Key Points
- Insider selling: CEO John C.M. Farquhar sold 22,562 shares at an average $27.46 for roughly $619,552, reducing his stake by 3.67%; director Julie Cullivan also sold 8,000 shares and a reported ~$56.1M shareholder sell-off plus a ~42% jump in short interest have added downward pressure on sentiment.
- Analyst outlook: Multiple firms (Stifel, JPMorgan, Canaccord, Wells Fargo) have lifted price targets toward ~$38–$40, leaving a MarketBeat consensus of "Moderate Buy" with an average target of $38.50 despite the stock trading near $27–30 and a negative PE.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 22,562 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $27.46, for a total value of $619,552.52. Following the completion of the transaction, the chief executive officer directly owned 591,656 shares of the company's stock, valued at approximately $16,246,873.76. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Heartflow Stock Performance
HTFL stock opened at $27.30 on Wednesday. The stock has a market capitalization of $2.32 billion and a PE ratio of -15.08. The stock has a fifty day simple moving average of $30.26. Heartflow, Inc. has a 1-year low of $25.38 and a 1-year high of $41.22.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on HTFL. Stifel Nicolaus boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. increased their price objective on Heartflow from $36.00 to $40.00 and gave the company an "overweight" rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on Heartflow from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. Finally, Wells Fargo & Company began coverage on shares of Heartflow in a report on Wednesday, January 28th. They set an "overweight" rating and a $38.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $38.50.
Get Our Latest Analysis on Heartflow
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. TFC Financial Management Inc. bought a new stake in shares of Heartflow during the third quarter valued at about $40,000. Legal & General Group Plc bought a new stake in Heartflow during the 3rd quarter worth approximately $59,000. Strs Ohio purchased a new stake in Heartflow in the 4th quarter worth approximately $99,000. Staley Capital Advisers Inc. purchased a new position in shares of Heartflow during the 4th quarter valued at $204,000. Finally, Connable Office Inc. bought a new position in shares of Heartflow in the fourth quarter worth $220,000.
Heartflow News Roundup
Here are the key news stories impacting Heartflow this week:
- Positive Sentiment: Analyst upgrades and bullish price-target revisions remain on the tape (Wells Fargo started coverage with an "overweight"; Canaccord, JPMorgan and Stifel have raised targets toward ~$38–$40), supporting medium-term upside expectations. MarketBeat Analyst Note
- Neutral Sentiment: Several smaller institutional investors added positions in recent quarters — a modest vote of confidence but not large enough to offset other flows on its own. MarketBeat Institutional Note
- Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at an average $27.46 (~$619.6k). Insider sales by the CEO can signal liquidity-taking and often weigh on sentiment. CEO Form 4
- Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), reducing her stake ~18%, which adds to negative insider-selling optics. Director Form 4
- Negative Sentiment: Reported large shareholder sell-off (headline noting ~$56.1M in stock sold) increases supply and likely pressured the share price. Major Shareholder Sale
- Negative Sentiment: Short interest surged in January to ~4.95M shares (up ~42% from mid‑January), representing ~5.8% of shares outstanding and ~5.9 days-to-cover — a material rise that can amplify downward moves as traders increase bearish positioning.
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
